Speakers
Yomei Matsuoka, MSc, RPh
Vice President, Pharmacoepidemiology and PMS Department, Daiichi Sankyo Co., Ltd., Japan
Mr. Matsuoka is Senior Director of Pharmacovigulance Department at Daiichi Sankyo Co., LTD. He joined Sankyo Co., LTD. in 1991, and has worked for Daiichi Sankyo Co., LTD.since 2007. After engagement in clinical development department and regulatory affairs department for over 20 years, and moved to pharmacovigilancedepartment. Currently, he is in charge of safety planning for the several therapeutic areas such as CV, oncology, CNS, vaccines and contrast agents.
Satoshi Fukunaga, PhD
, UCB Japan Co., Ltd., Japan
Teruyo Arato, PhD
Professor, Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Japan
She graduated Hokkaido University faculty of Pharmacy in1984 and received her Ph.D. in Medicine from the University of Tokyo in 1998. She joined the Pharmaceuticals and Medical Devices Evaluation Center, National Institute of Health Sciences (Japan) in 1999. From 2005 to 2011, she was a Review Director, Office of Biologics, PMDA (Pharmaceuticals and Medical Devices Agency) . She served as the Division Director of Human Resources Development Division, Office of Regulatory Science, PMDA from 2011-2012. She is currently working as a Professor of Hokkaido University Graduate School of Medicine. She is also a member of the Health Science Council of Ministry of Health, Labour and Welfare (MHLW) and outside expert of PMDA.
Yoshikata Furuya, MSc
Manager, General Affairs Division, Sankeien Hoshoukai Foundation, Japan
Yoshikata Furuya was Director of Vaccine Policy at MSD K.K. In this position, he was responsible for developing and executing policy strategies and action plan for MSD vaccines. Yoshikata Furuya had over 25 years' experience in the pharmaceutical and biotech industries including marketing, regulatory affairs and health policy.
Toshiko Ishibashi, PhD, RN
Oncology Medical Science Department, Medical Affairs Division, Daiichi Sankyo Co., Ltd., Japan
Toshiko Ishibashi is an Associate Director of Oncology Medical Science in Medical Affairs at Daiichi Sankyo Co., LTD. since 2020. She served Ono Pharmaceutical Company from 2018 to 2020. She was a Clinical Operations Manager at Abbvie, 2016-2018. She has experience as an assistant professor at the College of Nursing Art and Science, University of Hyogo. She has 16 years of clinical research experience as a Clinical Research Coordinator at Kumamoto University Hospital and St. Luke’s International Hospital.
Takaaki Ishine
Senior Clinical Research Specialist, MSD K.K., Japan
Kiyohito Nakai, PhD
Director, Pharmaceutical Safty Division, Ministry of Health, Labour and Welfare (MHLW), Japan
Yuko Owada
RA Functions Dept., Novartis Pharma K.K., Japan
Norikazu Takahata
President, Plus Action for Children, Japan
Nao Tsuchida, MD, PhD
Chief, National Hospital Organization Headquarters, Japan
Yoshiaki Uyama, PhD, RPh
Associate Executive Director, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Dr Yoshiaki Uyama is currently Associate Executive Director, Pharmaceuticals & Medical Devices Agency (PMDA) of Japan. He is responsible for regulatory science reserach in the agency. He has many experiences in new drug evaluation and real world data utilization, including the ICH E15, E16 and E17 Expert Working Groups, and Pharmacoepidemiology Discussion Group. He is also served as a visiting professor in Chiba University and Nagoya University.
Have an account?